234 related articles for article (PubMed ID: 28400509)
41. RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers.
Sumimoto H; Takano A; Teramoto K; Daigo Y
PLoS One; 2016; 11(11):e0166626. PubMed ID: 27846317
[TBL] [Abstract][Full Text] [Related]
42. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
43. Requirement for Ras/Raf/ERK pathway in naringin-induced G1-cell-cycle arrest via p21WAF1 expression.
Kim DI; Lee SJ; Lee SB; Park K; Kim WJ; Moon SK
Carcinogenesis; 2008 Sep; 29(9):1701-9. PubMed ID: 18296682
[TBL] [Abstract][Full Text] [Related]
44. Downregulated adaptor protein p66(Shc) mitigates autophagy process by low nutrient and enhances apoptotic resistance in human lung adenocarcinoma A549 cells.
Zheng Z; Yang J; Zhao D; Gao D; Yan X; Yao Z; Liu Z; Ma Z
FEBS J; 2013 Sep; 280(18):4522-30. PubMed ID: 23815759
[TBL] [Abstract][Full Text] [Related]
45. [A Case Report of Advanced Lung Adenocarcinoma Harboring KRAS Mutation
Treated with Anlotinib].
Su Y; Meng Z; Xu X; Wang X; Zuo R; Hou Y; Li K; Chen P
Zhongguo Fei Ai Za Zhi; 2018 May; 21(5):428-430. PubMed ID: 29764596
[TBL] [Abstract][Full Text] [Related]
46. Somatic Mutations Drive Distinct Imaging Phenotypes in Lung Cancer.
Rios Velazquez E; Parmar C; Liu Y; Coroller TP; Cruz G; Stringfield O; Ye Z; Makrigiorgos M; Fennessy F; Mak RH; Gillies R; Quackenbush J; Aerts HJWL
Cancer Res; 2017 Jul; 77(14):3922-3930. PubMed ID: 28566328
[TBL] [Abstract][Full Text] [Related]
47. Targeted elimination of senescent Ras-transformed cells by suppression of MEK/ERK pathway.
Kochetkova EY; Blinova GI; Bystrova OA; Martynova MG; Pospelov VA; Pospelova TV
Aging (Albany NY); 2017 Nov; 9(11):2352-2375. PubMed ID: 29140794
[TBL] [Abstract][Full Text] [Related]
48. Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators?
Lupu R; Menendez JA
Endocrinology; 2006 Sep; 147(9):4056-66. PubMed ID: 16809439
[TBL] [Abstract][Full Text] [Related]
49. Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2.
Chung LY; Tang SJ; Sun GH; Chou TY; Yeh TS; Yu SL; Sun KH
Clin Cancer Res; 2012 Aug; 18(15):4037-47. PubMed ID: 22696230
[TBL] [Abstract][Full Text] [Related]
50. Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas.
Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Yamada G; Hasegawa T; Miyagi Y; Niki T; Watanabe A; Takahashi H; Sakuma Y
Int J Oncol; 2018 Jul; 53(1):33-46. PubMed ID: 29658609
[TBL] [Abstract][Full Text] [Related]
51. KRAS mutation is associated with elevated myeloblastin activity in human lung adenocarcinoma.
Wiedl T; Collaud S; Hillinger S; Arni S; Burgess C; Kroll W; Schraml P; Soltermann A; Moch H; Weder W
Cancer Genomics Proteomics; 2012 Jan; 9(1):51-4. PubMed ID: 22210048
[TBL] [Abstract][Full Text] [Related]
52. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
[TBL] [Abstract][Full Text] [Related]
53. ERK1 and ERK2 activation modulates diet-induced obesity in mice.
Khan AS; Subramaniam S; Dramane G; Khelifi D; Khan NA
Biochimie; 2017 Jun; 137():78-87. PubMed ID: 28302472
[TBL] [Abstract][Full Text] [Related]
54. Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression.
Cicchini M; Buza EL; Sagal KM; Gudiel AA; Durham AC; Feldser DM
Cell Rep; 2017 Feb; 18(8):1958-1969. PubMed ID: 28228261
[TBL] [Abstract][Full Text] [Related]
55. FASN-dependent de novo lipogenesis is required for brain development.
Gonzalez-Bohorquez D; Gallego López IM; Jaeger BN; Pfammatter S; Bowers M; Semenkovich CF; Jessberger S
Proc Natl Acad Sci U S A; 2022 Jan; 119(2):. PubMed ID: 34996870
[TBL] [Abstract][Full Text] [Related]
56. Destabilization of Fatty Acid Synthase by Acetylation Inhibits De Novo Lipogenesis and Tumor Cell Growth.
Lin HP; Cheng ZL; He RY; Song L; Tian MX; Zhou LS; Groh BS; Liu WR; Ji MB; Ding C; Shi YH; Guan KL; Ye D; Xiong Y
Cancer Res; 2016 Dec; 76(23):6924-6936. PubMed ID: 27758890
[TBL] [Abstract][Full Text] [Related]
57. Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma.
Guibert N; Pradines A; Farella M; Casanova A; Gouin S; Keller L; Favre G; Mazieres J
Lung Cancer; 2016 Oct; 100():1-4. PubMed ID: 27597273
[TBL] [Abstract][Full Text] [Related]
58. [Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma].
Zhang H; Yang X; Qin N; Li X; Yang H; Nong J; Lv J; Wu Y; Zhang Q; Zhang X; Wang J; Zhou L; Zhang S
Zhongguo Fei Ai Za Zhi; 2015 Nov; 18(11):686-90. PubMed ID: 26582224
[TBL] [Abstract][Full Text] [Related]
59. Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.
Ricciuti B; Leonardi GC; Metro G; Grignani F; Paglialunga L; Bellezza G; Baglivo S; Mencaroni C; Baldi A; Zicari D; Crinò L
Expert Rev Respir Med; 2016; 10(1):53-68. PubMed ID: 26714748
[TBL] [Abstract][Full Text] [Related]
60. In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma.
Ambrogio C; Barbacid M; Santamaría D
Oncogene; 2017 Apr; 36(16):2309-2318. PubMed ID: 27775074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
